Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4430835 | 0.97 | ALDH1A1 (0.36) | ALDH1A1LMNATSHR | |
| SCHEMBL10147816 | 0.92 | ALDH1A1 (0.36) | ALDH1A1LMNATSHRTHRB | |
| SCHEMBL4436545 | 0.90 | ALDH1A1 (0.35) | ALDH1A1LMNATSHRTHRB | |
| SCHEMBL8356913 | 0.86 | CYP3A4 (0.40) | ALDH1A1TSHR | |
| SCHEMBL26739892 | 0.86 | ALDH1A1 (0.38) | ALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL2757538 | 0.83 | — | — | |
| SCHEMBL2735121 | 0.83 | ALDH1A1 (0.41) | ALDH1A1LMNATSHRSMN1; SMN2 | |
| SCHEMBL17640888 | 0.82 | TSHR (0.48) | TSHRTHRBHPGDSMN1; SMN2 | |
| SCHEMBL25840274 | 0.82 | HSD17B10 (0.41) | ALDH1A1TSHRTHRB | |
| SCHEMBL4830580 | 0.81 | ALDH1A1 (0.39) | ALDH1A1LMNATSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8003680-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100048669-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-7592366-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090181932-A1 | COMPOSITIONS CONTAINING O-SULFATE AND O-PHOSPHATE CONTAINING ARYL SULFONAMIDE DERIVATIVES USEFUL AS beta-AMYLOID INHIBITORS | WYETH (US) | 2009-07-16 | — | — | US | disclosed |
| US-7507833-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
| US-7226950-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230136194-A1 | TRIAZOLOPYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | ABCG2, CYP4F8, CYP3A5 | ALDH1A1 440/4885LMNA 3800/4885TSHR 2486/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | ALDH1A1 1652/4885LMNA 344/4885TSHR 3593/4885 |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | ALDH1A1 1555/4885LMNA 935/4885TSHR 1819/4885 |
| US-20100048669-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, GOT1 | ALDH1A1 553/4885LMNA 1806/4885TSHR 4020/4885 |
| US-20090181932-A1 | COMPOSITIONS CONTAINING O-SULFATE AND O-PHOSPHATE CONTAINING ARYL SULFONAMIDE DERIVATIVES USEFUL AS beta-AMYLOID INHIBITORS | SCN3A, HCN3, KCNN3 | ALDH1A1 3777/4885LMNA 1386/4885TSHR 2853/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | ALDH1A1 438/4885LMNA 2115/4885TSHR 4392/4885 |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | ALDH1A1 3814/4885LMNA 316/4885TSHR 1965/4885 |
| US-20170342068-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | HAVCR2, PYGL, OAT | ALDH1A1 695/4885LMNA 2667/4885TSHR 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.